- Home
- ACB vs PROC Comparison
ACB vs PROC Comparison
Compare ACB & PROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACB
- PROC
- Stock Information
- Founded
- ACB 2013
- PROC 1976
- Country
- ACB Canada
- PROC Luxembourg
- Employees
- ACB N/A
- PROC N/A
- Industry
- ACB Pharmaceuticals and Biotechnology
- PROC Biotechnology: Pharmaceutical Preparations
- Sector
- ACB Health Care
- PROC Health Care
- Exchange
- ACB Nasdaq
- PROC Nasdaq
- Market Cap
- ACB 315.4M
- PROC 203.1M
- IPO Year
- ACB N/A
- PROC N/A
- Fundamental
- Price
- ACB $5.51
- PROC $1.92
- Analyst Decision
- ACB Hold
- PROC
- Analyst Count
- ACB 1
- PROC 0
- Target Price
- ACB N/A
- PROC N/A
- AVG Volume (30 Days)
- ACB 659.5K
- PROC 11.6K
- Earning Date
- ACB 11-07-2024
- PROC 11-12-2024
- Dividend Yield
- ACB N/A
- PROC N/A
- EPS Growth
- ACB N/A
- PROC N/A
- EPS
- ACB N/A
- PROC 0.52
- Revenue
- ACB $203,838,819.00
- PROC $414,096,000.00
- Revenue This Year
- ACB $14.04
- PROC $5.54
- Revenue Next Year
- ACB $8.94
- PROC $8.54
- P/E Ratio
- ACB N/A
- PROC $3.72
- Revenue Growth
- ACB 12.30
- PROC N/A
- 52 Week Low
- ACB $2.84
- PROC $1.68
- 52 Week High
- ACB $9.35
- PROC $4.95
- Technical
- Relative Strength Index (RSI)
- ACB 46.80
- PROC 43.98
- Support Level
- ACB $5.46
- PROC $1.77
- Resistance Level
- ACB $5.66
- PROC $2.06
- Average True Range (ATR)
- ACB 0.17
- PROC 0.11
- MACD
- ACB 0.03
- PROC -0.02
- Stochastic Oscillator
- ACB 71.15
- PROC 25.86
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.
About PROC Procaps Group S.A.
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.